FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique
This article was originally published in The Tan Sheet
Executive Summary
Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug